Renaud A. Du Pasquier

Renaud A. Du Pasquier, M.D.
Full Professor

2015-present:
Full Professor at the Faculty of Biology and Medicine of the University of Lausanne Chairman of the Service of neurology
Head of the Laboratory of neuroimmunology
Department of clinical neurosciences, CHUV, Lausanne.

2011-2014:
Associate professor, médecin adjoint
Service of neurology, Department of clinical neurosciences; and Service of immunology and allergy, Department of medicine, CHUV, Lausanne

2005-2011:
Assistant Professor, Médecin associé
Divisions of Neurology and of Immunology and Allergy, CHUV, Lausanne.

September 2007-June 2008:
Acting Chairman in the Division of Neurology, CHUV, Lausanne.

2005:
Recipient of the Swiss National Foundation Professorship.

1999-2004:
Post-doc, then Instructor (Neurology and Division of Viral Pathogenesis, Prof. I.J. Koralnik), BIDMC, Harvard Medical School, Boston Massachusetts, USA. Research project: "Study of the role of CD8+ T cells in Progressive Multifocal Leukoencephalopathy, a demyelinating disease of the central nervous system caused by the polyomavirus JC".

2004:
Board-certified in Internal Medicine.

2001:
Board-certified in Neurology.

1997:
Thesis in Medicine, University of Geneva.

1992:
Diploma of Medicine, University of Geneva.

Awards
  • 2010:
    Faculty Price 2010 (Faculty of Biology and Medicine - FBM, University of Lausanne) for the E. Jaquiéry's work entitled: "Intrathecal immune response to EBV in early MS" published in European Journal of Immunology.
  • 2009:
    Best Poster in Basic Clinical Research at the Annual Congress of the Swiss Society for Allergology and Immunology 2009, Geneva. Increased EBV Reactivation in the Cerebrospinal Fluid of Patients with Early Multiple Sclerosis
    (E. Jaquiéry, first author, R. Du Pasquier, last author).
  • 2008:
    First BIOGEN DOMPE award for Clinical Research into Multiple Sclerosis
    (S. Jilek, first author and R. Du Pasquier, last author).
  • 2007:
    Recipient of the Abbott prize for the second best project submitted to the Swiss HIV Cohort Study in 2006
    (R. Du Pasquier, principal investigator).
Selected publications(for the exhaustive list, please go to the Uniscience list at http://www.unil.ch/unisciences/renauddupasquier)
  • Bacchetta F, Mathias A, Schluep M, Du Pasquier R, Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: an intriguing coincidence, Multiple Sclerosis Journal, in press
  • Mathias A, Perriard G, Canales M, Sorenson C, Delorenzi M, Schluep M, Du Pasquier RA, Increased ex vivo antigen presentation profile of B cells in multiple sclerosis, Multiple Sclerosis Journal, in press
  • Mathias A, Perriard G, Canales M, Vuilleumier F, Perrotta G, Schluep M, Du Pasquier RA, The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients, Neurol Neuroimmunol Neuroinflamm 2016 Feb 10;3(2):e209
  • Perriard G, Mathias A, Enz L, Canales M, Schluep M, Gentner M, Scharen-Wiemers N, Du Pasquier RA, Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes.J Neuroinflammation 2015 Jun 16;12(1):119
  • Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA, Natalizumab treatment alters the expression of T cell trafficking markers LFA-1 chain (CD11a) and CXCR3 in MS patients. Mult Scler J 2014;20(7):837-42.
  • Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux C, Gutmann C, Cusini A, Günthard H, Cavassini M, Vernazza P. Marked increase of astrocytic Marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 2013;27:203-10
  • Simioni S, Cavassini M, Annoni JM, Michel M, Iglesias K, Rimbault Abraham A, Calmy A, Müller H, Fayet A, Giacobini E, Hirschel B, Du Pasquier RA. Rivastigmine for HIV-associated neurocognitive disorders: a randomized, double-blind, placebo-controlled, crossover study, Neurology 2013;80(6):553-60
  • Antoniol C., Jilek S., Schluep M., Mercier N., Canales M., Le Goff G., Campiche C., Pantaleo G. and Du Pasquier R.A. Impairement of JCV-specific T cell response by corticotherapy: impact on PML-IRIS management ? Neurology 2012, 79:2258-2264. PudMed
  • Du Pasquier R.A., Jilek S., Kalubi M., Yerly S., Fux C.A., Gutmann C., Cusini A., Günthard H.F., Cavassini M., Vernazza P.L. and the Swiss HIV Cohort Study. Marked Increase of the Astrocytic Marker S100B in the Cerebrospinal Fluid of HIV-infected Patients on LPV/r-Monotherapy. AIDS 2012. In press. PubMed
  • Jilek S., Schluep M., Pantaleo G. and Du Pasquier R.A. MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.
    Neurol. Sci. 2012. In press. PubMed
  • Jilek S., Schluep M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., Pantaleo G. and Du Pasquier R.A.
    HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.
    J. Immunol. 2012, 188:4671-4680. PubMed
  • Schwab N., Höhn K.G., Schneider-Hohendorf T., Metz I., Stenner M.P., Jilek S., Du Pasquier R.A., Gold R., Meuth S.G., Ransohoff R.M., Brück W. and Wiendl H. Immunological and clinical consequences of treating a patient with natalizumab. Mult. Scler. 2012, 18:335-344. PubMed
  • Schwab N., Ulzheimer J.C., Fox R.J., Schneider-Hohendorf T., Kieseier B.C., Monoranu C.M., Staugaitis S.M., Welch W., Jilek S., Du Pasquier R.A., Brück W., Toyka K.V., Ransohoff R.M. and Wiendl H.
    Fatal PML associated with efalizumab therapy: Insights into integrin Lß2 in JC virus control.
    Neurology 2012, 78:458-467. PubMed
  • Guarda G., Braun M., Staehli F., Tardivel A., Förster I., Farlik M., Decker T., Du Pasquier R.A., Romero P. and Tschopp J. Type I IFN inhibits IL-1 production and inflammasome activation. Immunity 2011, 34:213-223. PubMed
  • Kuntzer T., Carota A., Novy J., Cavassini M. and Du Pasquier R.A. Rituximab is successful in an HIV-positive patient with IRIS-induced MuSK myasthenia gravis. Neurology 2011, 76:757-758. PubMed
  • Lysandropoulos A., Jaquiéry E., Jilek S., Pantaleo G., Schluep M. and Du Pasquier R.A. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol. 2011, 233 :240-244. PubMed
  • Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., Lecendreux M., Lammers G., Donjacour C., Du Pasquier R.A., Pfister C., Petit B., Mühlethaler M., and Tafti M. Tribbles homolog 2 as an autoantigen in human narcolepsy. J. Clin. Invest. 2010, 120:713-719. PubMed
  • Du Pasquier R.A. A promenade along the stream of demyelination. Curr. Opin. Neurol. 2010, 23:203-204. PubMed
  • Jaquiéry E., Jilek S., Schluep M., Le Goff G., Garcia M., Pantaleo G. and Du Pasquier R.A. Cytokine mRNA profile of Epstein-Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. J. Neuroimmunol. 2010, 225:167-170. PubMed
  • Jaquiéry E., Jilek S., Schluep M., Meylan P., Lysandropoulos A., Pantaleo G. and Du Pasquier R.A. Intrathecal immune responses to Epstein-Barr virus in early multiple sclerosis. Eur. J. Immunol. 2010, 40:878-887. PubMed
  • Jilek S., Jaquiéry E., Hirsch H.H., Lysandropoulos A., Canales M., Guignard L., Schluep M., Pantaleo G. and Du Pasquier R.A. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurology 2010, 9:264-272. PubMed
  • Lysandropoulos A.P. and Du Pasquier R.A. Demyelination as a complication of new immunomodulatory treatments. Curr. Opin. Neurol. 2010, 23:226-233. PubMed
  • Simioni S., Cavassini M., Anonni J.-M., Rimbault-Abraham A., Bourquin I., Schiffer V., Calmy A., Chave J.-P., Giacobini E., Hirschel B. and Du Pasquier R.A. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250. PubMed
  • Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G. and Du Pasquier R.A. Strong EBV-specific CD8+ T cell response in patients with early multiple sclerosis. Brain 2008, 131:1712-1721. PubMed
  • Jilek S., Kuhle J., Meylan P., Reichhart M.D., Pantaleo G. and Du Pasquier R.A. Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. J. Neuroimmunol. 2007, 192:192-197. PubMed
  • Jilek S., Schluep M., Rosseti A.O., Guignard L., Le Goff G., Pantaleo G. and Du Pasquier R.A. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin. Immunol. 2007, 123:105-113. PubMed
  • Vulliemoz S., Lurati-Ruiz F., Borruat F.X., Delavelle J., Koralnik I.J., Kuntzer T., Bogousslavsky J., Picard F., Landis T. and Du Pasquier R.A. Favourable outcome of progressive multifocal leukoencephalopathy in two patients with dermatomyositis. J. Neurol. Neurosurg. Psychiatry 2006, 77:1079-1082. PubMed
  • Du Pasquier R.A., Stein M.C., Lima M.A., Dang X., Jean-Jacques J., Zheng Y., Letvin N.L. and Koralnik I.J. JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients. J. Neuroimmunol. 2006, 176:181-186. PubMed
  • Du Pasquier R.A., Autissier P., Zheng Y., Jean-Jacques J. and Koralnik I.J. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005, 19:2069-2076. PubMed
  • Du Pasquier R.A., Schmitz J.E., Jean-Jacques J., Zheng Y., Gordon J., Khalili K., Letvin N.L. and Koralnik I.J. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J. Virol. 2004, 78:10206-10210. PubMed
  • Du Pasquier R.A., Kuroda M.J., Schmitz J.E., Zheng Y., Jean-Jacques J. and Koralnik I.J. A prospective study demonstrates an association between JCV-specific CTL and the early control of Progressive Multifocal Leukoencephalopathy. Brain 2004, 127:1970-1978. PubMed
  • Du Pasquier R.A., Schmitz J.E., Jean-Jacques J., Zheng Y., Gordon J., Khalili K., Letvin N. and Koralnik I.J. Detection of JC Virus-specific cytotoxic T lymphocytes in healthy individuals. J. Virol. 2004, 78:10206-10210. PubMed
  • Du Pasquier R.A., Kuroda M.J., Schmitz J.E., Zheng Y., Martin K., Peyerl F.W., Lifton M., Gorgone D., Autissier P., Letvin N. and Koralnik I.J. Low Frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1p36 in patients with proven or possible Progressive Multifocal Leukoencephalopathy. J. Virol. 2003, 77:11918-11926. PubMed
  • Du Pasquier R.A., Corey S., Margolin D.H., William K., Pfister L.A., Mc Key J.J., De Girolami U., Joseph J.T. and Koralnik I.J. Productive Infection of Cerebellar Granule Cell Neurons by JC Virus in an HIV-infected Individual with Progressive Multifocal Leukoencephalopathy. Neurology 2003, 61:775-782. PubMed
  • Jilek S., Walter E., Merkle H.P. and Corthésy B. Modulation of allergic responses in mice using poly(lactide co-glycolide) biodegradable microparticles. J. Allergy Clin. Immunol. 2004, 114:943-950. PubMed
  • Jilek S., Barbey C., Spertini F. and Corthésy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J. Immunol. 2001, 166:3612-3621. PubMed
 Dernière mise à jour le 11/04/2019 à 15:38